Cyclin L1 antibody (AA 351-450)
Quick Overview for Cyclin L1 antibody (AA 351-450) (ABIN872995)
Target
See all Cyclin L1 (CCNL1) AntibodiesReactivity
Host
Clonality
Conjugate
Application
-
-
Binding Specificity
- AA 351-450
-
Cross-Reactivity
- Chimpanzee
-
Predicted Reactivity
- Human,Mouse,Rat,Dog,Cow,Sheep,Pig,Chimpanzee
-
Purification
- Purified by Protein A.
-
Immunogen
- KLH conjugated synthetic peptide derived from human Cyclin L/CCNL1
-
Isotype
- IgG
-
-
-
-
Application Notes
-
WB 1:300-5000
ELISA 1:500-1000
IHC-P 1:200-400
IHC-F 1:100-500
IF(IHC-P) 1:50-200
IF(IHC-F) 1:50-200
IF(ICC) 1:50-200 -
Restrictions
- For Research Use only
-
-
-
Format
- Liquid
-
Concentration
- 1 μg/μL
-
Buffer
- 0.01M TBS( pH 7.4) with 1 % BSA, 0.02 % Proclin300 and 50 % Glycerol.
-
Preservative
- ProClin
-
Precaution of Use
- This product contains ProClin: a POISONOUS AND HAZARDOUS SUBSTANCE, which should be handled by trained staff only.
-
Storage
- 4 °C,-20 °C
-
Storage Comment
- Shipped at 4°C. Store at -20°C for one year. Avoid repeated freeze/thaw cycles.
-
Expiry Date
- 12 months
-
-
- Cyclin L1 (CCNL1)
-
Alternative Name
- Cyclin L
-
Background
-
Synonyms: Ania 6a, BM 001, CCNL 1, CCNL1, CCNL1_HUMAN, Cyclin L ania 6a, Cyclin L, Cyclin L gamma, Cyclin L1, Cyclin-L, Cyclin-L1.
Background: Transcriptional regulator which participates in regulating the pre-mRNA splicing process. Seems to be involved in the regulation of RNA polymerase II (pol II). Functions in association with cyclin-dependent kinases (CDKs) and has a role in the second step of splicing. May be a candidate proto-oncogene in head and neck squamous cell carcinomas (HNSCC). Inhibited by the CDK-specific inhibitor p21.Tissue specificity,Ubiquitous with higher level in thymus. Overexpression in primary tumors of head and neck squamous cell carcinomas (HNSCC).
-
Gene ID
- 57018
Target
-